Study guide

8.5 Diuretics and Decongestion Strategies

AACN Cardiac Medicine Certification CMC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview and the CMC Test Plan

1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them

2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease

2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy

3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease

3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup

4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions

4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation

5 Chapter 5: Vascular Conditions and Vascular Interventions

5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications

6 Chapter 6: Shock States and Mechanical Circulatory Support

6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD

7 Chapter 7: Cardiac Procedures and Structural Heart Interventions

7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications

8 Chapter 8: Cardiovascular Pharmacology

8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure

9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary

9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients

10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral

10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients

11 Chapter 11: Monitoring and Diagnostics

11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography

12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions

12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease

8.5 Diuretics and Decongestion Strategies

Key Takeaways Explain This Topic AI

IV loop equivalence is furosemide 20 mg = bumetanide 1 mg = torsemide 10-20 mg; torsemide and bumetanide have 80-100% oral bioavailability versus furosemide's erratic 10-100%, which is why they are preferred when gut edema is present.

A patient already on a home oral loop diuretic should receive an IV dose of 2 to 2.5 times the total daily home oral dose; once at ceiling, increase frequency rather than the size of the single dose.

A spot urine sodium below 50-70 mEq/L measured 1-2 hours after an IV loop dose, or hourly urine output below 100-150 mL/h, predicts poor natriuretic response and should trigger doubling the dose immediately.

Metolazone 2.5-10 mg or chlorothiazide 500-1,000 mg IV must be given 30-60 minutes before the loop dose so that distal blockade is established when the sodium load arrives.

Acetazolamide 500 mg IV daily added to IV loop therapy raised successful decongestion at day 3 from 30.5% to 42.2% in the ADVOR trial and simultaneously corrects hypochloremic contraction alkalosis.

Last updated: August 2026

Why Decongestion Is the Whole Admission

Test-plan item III.C.3 is diuretics, and on the CMC exam diuretic questions are really decongestion questions. Most heart failure admissions are driven by congestion rather than low output, and residual congestion at discharge is the single strongest predictor of 30-day readmission and death . The nurse controls almost every variable that determines whether decongestion succeeds: whether the dose was actually adequate, whether the response was measured early enough to act on, and whether electrolytes were replaced before they stopped the diuresis.

Loop Diuretic Pharmacology

Loop diuretics inhibit the sodium-potassium-2-chloride cotransporter in the thick ascending limb of the loop of Henle, blocking reabsorption of roughly 25% of filtered sodium. They circulate about 95% bound to albumin, are filtered poorly, and must be actively secreted into the tubular lumen by organic anion transporters. This has three consequences that explain most bedside failures: the drug must reach the lumen to work, competing anions block secretion, and the response is threshold-dependent - below a certain luminal concentration nothing happens, and above the ceiling a larger single dose adds nothing.

Agent IV equivalent Oral equivalent Oral bioavailability Half-life Practical note

Furosemide 20 mg 40 mg 10-100%, averaging about 50% and highly erratic 1.5-2 h Falls further with bowel wall edema; the workhorse but the least predictable orally

Bumetanide 1 mg 1 mg 80-100%, reliable 1-1.5 h 1:1 IV-to-oral conversion

Torsemide 10-20 mg 20 mg 80-100%, reliable 3-4 h Longest acting; preferred when gut edema makes oral furosemide unreliable

Ethacrynic acid 50 mg 50 mg Variable 2-4 h Non-sulfonamide option for true sulfa hypersensitivity; more ototoxic

Ceiling dose is the single IV dose above which no additional natriuresis occurs: roughly 40 mg of furosemide equivalent in normal renal function, 80-160 mg in heart failure, and up to 160-200 mg with an eGFR below 30 mL/min/1.73 m2. Once you are at ceiling, increase the frequency, not the size, of the dose - twice or three times daily, or convert to an infusion.

Dosing the naive versus the chronically treated patient. A diuretic-naive patient starts at furosemide 20-40 mg IV. A patient already on a home oral loop diuretic must receive an IV dose equal to 2 to 2.5 times the total home oral dose , given as at least twice-daily dosing - the strategy tested in the DOSE trial, where the high-dose arm produced greater dyspnea relief, greater weight and net fluid loss, and more transient creatinine rise that did not translate into worse outcomes. The same trial found no meaningful difference between intermittent bolus and continuous infusion for the primary endpoints, so an infusion is not automatically superior. Reserve continuous infusion (furosemide 5-20 mg/h or bumetanide 0.5-2 mg/h after a loading bolus) for severe diuretic resistance or right-sided failure where maintaining a steady luminal concentration above threshold matters most.

Administration rate is a safety item. Push furosemide no faster than 4 mg/min - a 20-40 mg dose over 1-2 minutes, with doses above about 120 mg given as an infusion rather than a push. Bumetanide is limited to 1 mg/min. Exceeding these rates, particularly with concurrent aminoglycosides or renal failure, causes tinnitus and usually reversible sensorineural hearing loss.